Valneva SE American Depositary Shares (VALN) — 分析摘要
Valneva SE American Depositary Shares(VALN)的市值为622.04百万美元,最近一年的营收同比增长了+7.8%。净利润率为-66.0%。当前市盈率为-4.8倍。
核心要点
- 营收同比变化+7.8%
- 净利润率-66.0%
- 市盈率-4.8倍
VALN的营收增长为+7.8%,市盈率为-4.8倍。
Valneva SE American Depositary Shares (VALN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -2.0x — 盈利不足以覆盖利息支出
营业利润率为 -47.0% — 经营亏损显著
净利率为 -66.0% — 亏损显著
最新报表显示自由现金流为负。
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
员工人数
674
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。